Pharsight Collaborates with LabLogic to Link WinNonlin(R), Debra(TM) Products Enhanced Interoperability Increases Utility of Both Products
MOUNTAIN VIEW, Calif., Sept. 15 /PRNewswire-FirstCall/ — Pharsight Corporation (OTC Bulletin Board: PHST – News), a leading provider of software and strategic services designed to optimize clinical drug development, today announced that it has signed a cooperation agreement with LabLogic Systems Limited to enhance the link between Debra, LabLogic’s drug metabolism Laboratory Information Management System, and Pharsight’s WinNonlin software for pharmacokinetic, pharmacodynamic and non-compartmental analysis.
WinNonlin’s Automation Application Programming Interface (API) in Debra 5.6.3 enables users of both systems to select time-concentration data in Debra and export it to WinNonlin for analysis without infringing Part 11/GLP compliance. WinNonlin is launched from Debra with a single key press, transferring the chosen data automatically and avoiding the transcription errors that easily occur when copying and pasting between systems.
“Many of our customers have asked for a tool to seamlessly integrate Debra with other pharmacokinetic data analysis systems,” said Huw Loaring, Systems Director of LabLogic Systems. “Working closely with Pharsight ensures our mutual clients get a compliant, integrated solution without the need for manual manipulation of data outside our applications.”
“This collaboration is evidence of Pharsight’s commitment to its customers to continually improve the functionality and quality of our products,” said Dan Weiner, Ph.D., senior vice president, Software Products at Pharsight Corporation. “The interoperability with LabLogic’s Debra product frees users from the tedium of moving data around and allows them to focus on their science.”
About Pharsight Corporation
Pharsight Corporation develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers’ development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at www.pharsight.com .
About LabLogic
LabLogic Systems Limited started trading in 1979, initially supplying Radio HPLC, Radio TLC and Radio GC measurement instrumentation throughout the research and development industry. The company then became involved in the supply and integration of applications software to compliment its growing instrument product range. From this background, LabLogic proceeded to provide bespoke LIMS for ADME drug metabolism laboratories and has progressed to providing flexible ‘off the shelf’ solutions, which has resulted in LabLogic now being viewed as the world leading supplier of Laboratory Information Management Systems.
Safe Harbor
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding Pharsight’s performance. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in Pharsight’s research and development focus or operating strategies, the failure to develop new products and services or to keep pace with technological advancements, delays in the release of new products and services, the failure of the market for Pharsight’s products and services to develop as expected, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10- Q, as filed with the Securities and Exchange Commission on August 14, 2006. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
NOTE: Trademarks and Registered Trademarks
Pharsight and WinNonlin are registered trademarks of Pharsight Corporation. Debra and LabLogic are trademarks or registered trademarks of LabLogic Systems Limited.
